Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects.
COVID-19 diagnostic assays
SARS-CoV-2 serology
neutralizing activity
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
20
07
2020
revised:
13
10
2020
accepted:
14
10
2020
pubmed:
17
10
2020
medline:
20
3
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.
Identifiants
pubmed: 33064340
doi: 10.1002/jmv.26605
pmc: PMC7675753
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2160-2167Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Front Mol Biosci. 2020 Jul 03;7:157
pubmed: 32719810
Sci China Life Sci. 2021 Mar;64(3):482-485
pubmed: 32876887
Cell Death Discov. 2020 May 26;6:38
pubmed: 32501411
NPJ Vaccines. 2020 May 28;5(1):43
pubmed: 32528732
J Med Virol. 2021 Apr;93(4):2160-2167
pubmed: 33064340
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32848041
Rev Med Virol. 2021 Mar;31(2):e2170
pubmed: 33350017
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Nat Commun. 2021 Mar 22;12(1):1813
pubmed: 33753738
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Clin Chem. 2020 Aug 1;66(8):1055-1062
pubmed: 32402061
Stat Med. 1997 Oct 15;16(19):2143-56
pubmed: 9330425
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337